Replies to post #8768 on Momenta Pharmaceuticals, Inc. (MNTA)

[Regulardoc]

Agree with your comments; however, I was referencing the mention that Copaxone was an "intravenous" treatment, whereas it is not given IV.

[DewDiligence]

One of Teva’s non-Orange-Book patents being challenged by MNTA/NVS/MYL (number 5,800,808) expires 9/1/15—see #msg-54113660.